Stocks Health care IDYA
NASDAQ · Health careIDEAYA Biosciences, Inc. (IDYA)
It posted a net loss of $420M. In fiscal 2025 capital spending exceeded operating cash flow by $73.5M. At September 30, 2026 it held $261.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about IDEAYA Biosciences, Inc.
- Net worth
- IDEAYA Biosciences, Inc. has a market value (market cap) of $3B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $218.7M (+3,024.4% year on year), with a net loss of $113.7M.
- Cash flow
- In fiscal 2025 operations used $71.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- IDEAYA Biosciences, Inc.'s next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What IDEAYA Biosciences, Inc. does
IDEAYA Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IDYA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $218.7M | -$113.7M | -$1.28 | -$73.5M |
| 2024 | $7M | -$274.5M | -$3.36 | -$251.4M |
| 2023 | $23.4M | -$113M | -$1.96 | -$117.6M |
| 2022 | $50.9M | -$58.7M | -$1.42 | -$90.6M |
| 2021 | $27.9M | -$49.8M | -$1.41 | -$58.4M |
| 2020 | $19.5M | -$34.5M | -$1.40 | $55M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IDYA ranks in Health care
Latest SEC filings
What IDEAYA Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 95% to $10.2M versus the same quarter last year; diluted EPS -$1.22 versus $1.33.
- November 3, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 4, 2026
- August 4, 2026
- July 31, 2026Passive stake (5% or more) SCHEDULE 13G
- June 23, 2026
- June 10, 2026Other event 8-K
- June 3, 2026Other event 8-K
Insider trades
What the people running IDEAYA Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $985.4K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 6, 2026 | Hata Yujiro SPresident and CEO, Director | Exercised options | 26,338 | $113.5K |
| October 6, 2026 | Hata Yujiro SPresident and CEO, Director | Soldpre-planned (10b5-1) | 25,538 | $954.8K |
| October 6, 2026 | Hata Yujiro SPresident and CEO, Director | Soldpre-planned (10b5-1) | 800 | $30.6K |
| July 7, 2026 | Ruiz Briseno AndresChief Accounting Officer | Exercised options | 9,550 | $122.8K |
| July 7, 2026 | Ruiz Briseno AndresChief Accounting Officer | Soldpre-planned (10b5-1) | 9,550 | $382.1K |
| March 2, 2026 | Stein JeffreyDirector | Bought | 50,000 | $1.6M |
| November 28, 2025 | Ruiz Briseno AndresSee Remarks | Received as pay | 1,253 | $21.2K |
| November 28, 2025 | Snyder Douglas B.SVP, General Counsel | Received as pay | 1,041 | $17.6K |
Who owns IDYA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 8.3% | May 15, 2026 |
| Capital Research Global Investors13G, passive | 6% | February 12, 2026 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 5.2% | August 14, 2026 |
| Vanguard Capital Management13G, passive | 5.08% | July 31, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 284 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 14,109,431 | +937,328 |
| BlackRock, Inc. | 8,893,260 | +451,127 |
| Jupiter Topco LLC | 8,579,881 | new |
| Capital Research Global Investors | 5,344,701 | +181,158 |
| Baker Bros. Advisors LP | 5,010,030 | +1,063,515 |
| State Street Corp | 4,548,911 | +767,744 |
| Vanguard Capital Management LLC | 4,132,646 | +400,224 |
| Logos Global Management LP | 3,000,000 | -450,000 |
| Adage Capital Partners GP, L.L.C. | 2,715,391 | -108,109 |
| Deerfield Management Company, L.P. | 2,714,503 | +1,184,495 |
| Geode Capital Management, LLC | 2,425,602 | -75,122 |
| Morgan Stanley | 1,931,491 | +71,038 |
| Dimensional Fund Advisors LP | 1,661,281 | +327,803 |
| Alliancebernstein L.P. | 1,627,521 | +1,526,735 |
| Fiera Capital Corp | 1,445,885 | -1,081,191 |
| Federated Hermes, Inc. | 1,431,630 | -1,555,477 |
| GSK plc | 1,333,333 | 0 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,269,889 | +168,744 |
| Goldman Sachs Group Inc | 1,231,614 | -424,003 |
| Candriam S.C.A. | 1,092,301 | -15,407 |
Insiders
4 insiders reported holding 773,522 shares in total, about $24.2M at the last price.
| Holder | Shares |
|---|---|
| Hata Yujiro SPresident and CEO, Director | 690,695 |
| Stein JeffreyDirector | 54,281 |
| Ruiz Briseno AndresChief Accounting Officer | 26,466 |
| Snyder Douglas B.SVP, General Counsel | 2,080 |
Questions about IDYA
What does IDEAYA Biosciences, Inc. do?
IDEAYA Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as IDYA. Its shares trade on NASDAQ under the ticker IDYA.
What is IDEAYA Biosciences, Inc.'s net worth?
IDEAYA Biosciences, Inc. has a market value (market cap) of $3B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is IDEAYA Biosciences, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $420M.
When did IDEAYA Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is IDEAYA Biosciences, Inc.'s next earnings report?
IDEAYA Biosciences, Inc.'s next report is expected around February 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IDYA with
Follow IDYA
Get an email when IDEAYA Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values IDEAYA Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.